Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Euroscreen is a Belgian biotechnology company specializing in G Protein-Coupled Receptor (GPCR) drug discovery and development. The company operates through two main divisions: Euroscreen Fast, which provides high-quality GPCR screening services and assay development to the pharmaceutical industry, and a drug discovery unit that was rebranded as Ogeda. Ogeda's lead program, fezolinetant, a non-hormonal treatment for menopausal hot flashes, led to the company's acquisition by Astellas Pharma in 2017. Today, Euroscreen continues to be a recognized leader in GPCR-based research, leveraging its extensive library of human GPCRs to support drug discovery programs globally.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Euroscreen.